Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb study of cannabidiol for the prevention of acute Graft versus Host Disease GvHD following allogeneic hematopoietic cell transplantation (HCT).

Trial Profile

Phase IIb study of cannabidiol for the prevention of acute Graft versus Host Disease GvHD following allogeneic hematopoietic cell transplantation (HCT).

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2018 According to a Kalytera Therapeutics media release, the company plans to announce interim data from the study later this year and expects to complete the study in Q2 2019.
    • 20 Sep 2018 According to a Kalytera Therapeutics media release, the company is expanding this study to include one additional site in Israel, and up to four additional sites in other jurisdictions, including Australia.
    • 07 Dec 2017 According to a Kalyteta Therapeutics media release, the principal investigator of the study is Daniel Couriel, M.D., M.S., Director of the Bone Marrow Transplant Program at the University of Utah Health Sciences, School of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top